HCPCS code J3101: Tenecteplase billing units and coverage

Key takeaways

HCPCS code J3101 describes injection, tenecteplase (TNKase), 1 mg. It is billed per milligram under Medicare Part B for both of the drug’s FDA-approved indications.

TNKase carries two labeled indications. The FDA approved acute ischemic stroke on March 3, 2025, alongside the existing acute STEMI indication. Neither use is off-label.

The stroke dose is half the STEMI dose at every weight tier. Stroke runs 15 mg to 25 mg, so 15 to 25 units. STEMI runs 30 mg to 50 mg, so 30 to 50 units.

Medicare reimburses J3101 at ASP+6% in hospital outpatient and physician office settings. Rates update quarterly, so verify the current rate in the CMS ASP drug pricing file before billing.

Practice management software like Pabau pairs ICD-10 and HCPCS code lookup libraries with required-field checks, then submits the finished claim electronically. Fewer J3101 lines leave the practice incomplete.

HCPCS code J3101 bills injection, tenecteplase, 1 mg, so one unit equals one milligram administered. The code now covers two FDA-approved indications: acute ischemic stroke and acute STEMI. That matters more than it sounds, because the stroke dose is half the STEMI dose at every weight tier.

Below are both dose tables, the ICD-10 codes that carry medical necessity, the NDC and wastage rules, and the checks worth running before you submit.

HCPCS code J3101 covers one milligram of tenecteplase

J3101 is a Level II HCPCS drug code maintained by the Centers for Medicare and Medicaid Services (CMS). Its official descriptor is Injection, tenecteplase, 1 mg.

The code sits in the J-code range, which covers drugs given by routes other than oral, so injection, infusion, or inhalation in an outpatient setting.

Tenecteplase now treats two emergencies, both on label

Tenecteplase carries two labeled indications, and neither is off-label use. The FDA approved acute ischemic stroke (AIS) in adults on March 3, 2025.

The existing indication, reducing the risk of death from acute ST elevation myocardial infarction (STEMI), still stands. Tenecteplase itself is a tissue plasminogen activator (tPA), engineered for single-bolus intravenous delivery.

That second approval doubled the number of dose tables a coder works from. The stroke dose tops out at 25 mg. The STEMI dose tops out at 50 mg. One code bills both.

Alteplase needs a prolonged infusion. Tenecteplase does not, and its weight-based single-dose protocol is what makes it practical where infusion logistics are a barrier.

The dose is therefore fixed at the moment of injection, and it varies only by patient weight and indication.

• Mechanism: Selectively binds fibrin and converts plasminogen to plasmin, dissolving the clot at the occlusion site
• Labeled indication 1 (section 1.1): Acute ischemic stroke in adults, treated within 3 hours of symptom onset
• Labeled indication 2 (section 1.2): Reducing the risk of death from acute STEMI in adults
• Route of administration: Single intravenous bolus over 5 seconds
• Clinical setting: Hospital emergency department, stroke unit, hospital outpatient, cardiac catheterization lab, or physician office with emergency capability
• Billing implication: Dose is weight-based and fixed per administration; each milligram billed as one unit of J3101

One practical consequence: because the drug goes in during a stroke or cardiac event, the paperwork gets written under pressure. Confirm the administered dose from the medication administration record (MAR) or the procedural note, never from the ordered dose.

Your J3101 unit count equals the milligrams administered

One billing unit of J3101 equals 1 mg of tenecteplase administered. The drug is dosed by patient body weight, and the weight tiers are identical for both indications. Only the dose inside each tier changes, and the stroke dose is exactly half the STEMI dose.

So the same 75 kg patient generates 20 units on a stroke claim and 40 units on a STEMI claim. The chart below sets both tables side by side, which is the fastest way to see how far apart the two unit counts sit.

Stroke doses stop at 25 mg, so units stop at 25

For acute ischemic stroke, TNKase goes in as a single intravenous bolus over 5 seconds. Treatment starts as soon as possible and within 3 hours of symptom onset. The maximum recommended dose is 25 mg, which is 25 units of J3101.

Fractional units: two stroke tiers land on half-milligram doses, 17.5 mg and 22.5 mg. Some payer systems accept a decimal quantity on the drug line, and others require whole units. Confirm the convention with the payer or MAC before submitting 17.5 or 22.5 units, and never round the documented dose itself.

STEMI doses run double, from 30 to 50 units

For acute STEMI, the bolus also goes in over 5 seconds, as soon as possible after symptom onset. The maximum recommended dose is 50 mg, so no STEMI claim should exceed 50 units.

Common billing error: billing the ordered dose rather than the administered dose. If a 90 kg patient receives 50 mg but the order lists a provisional 45 mg, bill the 50 mg. The claim follows the medication administration record, not the order.

Medicare pays J3101 at ASP plus 6%, updated quarterly

Medicare Part B reimburses J3101 under the Average Sales Price plus 6% (ASP+6%) methodology used for provider-administered drugs.

The rate applies in both hospital outpatient department (HOPD) and physician office settings. CMS recalculates ASP quarterly, so the dollar figure per unit changes every January, April, July, and October.

To find the current rate, use the CMS Physician Fee Schedule lookup tool or the quarterly ASP drug pricing file on cms.gov. Pull the new file on the first working day of each quarter. Update charge capture from it, rather than waiting for a payment variance to surface the change.

Reading the remittance advice after adjudication is the fastest way to catch a stale rate on J3101. A payment that does not match the current quarter usually points to a claim lag or a payer contract override.

• ASP+6% applies in: Hospital outpatient (Place of Service 22) and physician office (Place of Service 11)
• Rate update frequency: Quarterly (January, April, July, October)
• Current rate source: CMS ASP drug pricing file (quarterly release on cms.gov)
• Medicaid rates: Vary by state; some states use NADAC or WAC-based pricing rather than ASP

Part B covers tenecteplase when the diagnosis matches the label

Medicare covers tenecteplase under Part B when a covered outpatient setting administers it and the record supports medical necessity.

Coverage follows the FDA-approved indications, and there are now two. A stroke claim and a STEMI claim are both coverable when the diagnosis code and the clinical record line up.

Claims submitted without a supporting I63.x or I21.x code are routinely denied.

• Diagnosis must align with an ICD-10-CM code for one of the two labeled indications: acute ischemic stroke (I63 series) or acute STEMI (I21 series)
• Documentation must support medical necessity: clinical indication, presenting symptoms, and treatment urgency
• On a stroke claim, the record must show the time of symptom onset and that the bolus fell inside the 3-hour window
• Drug must be administered by a physician or qualified healthcare professional in a Part B-covered setting
• Neither labeled indication is off-label, so neither needs compendia support. A use outside both indications does, along with an LCD or NCD reference.
• Prior authorization requirements vary by Medicare Advantage plan; confirm with the specific plan before administration when time permits

Local Coverage Determinations (LCDs) from the relevant Medicare Administrative Contractor (MAC), such as Noridian, CGS, or Palmetto, may add documentation requirements. Check the applicable MAC’s site for current LCD guidance on J3101.

Watch one lag effect. Because the stroke indication is recent, some payer edit tables still key J3101 to cardiac diagnoses alone. If a stroke claim denies for a diagnosis mismatch, appeal with the current prescribing information attached.

How a J3101 claim moves from purchase to payment

Tenecteplase is billed under the buy-and-bill model. The provider buys the drug from a wholesaler or specialty pharmacy, administers it, then bills the payer for both the drug and the administration service.

That order matters for cash flow. Acquisition cost is paid upfront, and reimbursement arrives 30 to 45 days later.

1. Acquire the drug: Purchase tenecteplase from an authorized wholesaler, stocking both the 25 mg and 50 mg vials if the practice treats stroke and STEMI. Record the acquisition cost, NDC, and lot number.
2. Administer and document: Record the exact dose administered (mg) in the MAR. Note patient weight, the indication, symptom onset time, administration time, route, and clinician identity.
3. Charge capture: Enter J3101 with units equal to the milligrams administered. Link the administration code on the same claim, which for a single IV bolus is CPT 96374.
4. NDC and wastage: Report the 11-digit NDC, quantity, and unit of measure on the claim line. Add a JW line or a JZ modifier for the discarded amount.
5. Submit and reconcile: Send the claim electronically. Monitor remittance advice for ASP rate application and clear any drug-quantity edits promptly.

The diagnosis code decides whether J3101 gets paid

Every J3101 claim needs a supporting ICD-10-CM diagnosis code that establishes medical necessity. Which series you draw from depends on the indication.

Stroke claims use the I63 cerebral infarction series, and STEMI claims use the I21 series. Both sit in the wider ICD-10-CM code library if you need to check a neighboring subcategory.

Stroke claims draw from the I63 series

The I63 series carries medical necessity for a stroke bolus. Code to the documented mechanism, the documented vessel, and the side of the body.

The table below lists the subcodes that appear most often on thrombolytic claims.

Two traps in the I63 series. I63.8 became a non-billable parent code on October 1, 2019, split into I63.81 and I63.89, so a claim carrying I63.8 rejects as an invalid code. Laterality is also required on most subcategories, and an unspecified-side code invites a medical necessity review on a drug this expensive.

One more distinction is worth building into the workflow. A receiving facility does not bill J3101 for a dose given somewhere else. It reports Z92.82 instead, which flags tPA administered at another facility within the previous 24 hours.

STEMI claims draw from the I21 series

The I21 series covers the cardiac indication. Use the code that names the infarct site, because the unspecified option draws documentation requests.

Use the most specific ICD-10-CM code the documentation supports. Payers apply medical necessity edits when the submitted diagnosis does not align with an indication the applicable LCD supports. Confirm coverage linkage with your MAC before billing an NSTEMI diagnosis with J3101.

Report the NDC for the vial you opened, not the one on file

Most Medicaid programs and many Medicare Advantage plans require the 11-digit National Drug Code (NDC) on drug claim lines. For tenecteplase billed as J3101, the NDC must match the package administered. TNKase ships in two vial strengths, and each carries its own NDC.

NDC numbers change when Genentech / Roche revises packaging, so confirm current values through the NLM HCPCS API or a current NDC file. Hardcoded values in the practice management system go stale.

The 25 mg vial exists to serve the stroke indication, since a stroke dose of 15 mg to 25 mg is drawn from it. A STEMI dose of 30 mg to 50 mg needs the 50 mg vial. So the NDC on a stroke claim is usually not the NDC on a STEMI claim.

How to report the NDC on a claim: Enter the 11-digit NDC in the shaded area of Box 24. On the 837P electronic transaction, use the NDC qualifier field instead. Include the qualifier “N4”, the 11-digit code, the unit of measure qualifier “UN”, and the quantity administered.

• NDC format required: 11 digits (5-4-2 format), no hyphens
• Quantity: report the total milligrams administered (same as J3101 units)
• Unit of measure qualifier: “UN” (units) for tenecteplase
• Source: use the lot number and package insert to confirm the NDC for the vial administered

Discarded tenecteplase needs a JW line or a JZ attestation

Both TNKase vials are single-dose containers, so Medicare’s discarded-drug policy applies to J3101. A 15 mg stroke dose drawn from the 25 mg vial leaves 10 mg behind. Part B pays for that remainder when the claim reports it properly.

• Administered amount: first J3101 line, units equal to the milligrams that went into the patient, no modifier
• Discarded amount: second J3101 line with modifier JW, units equal to the milligrams left in the vial
• Nothing discarded: a single J3101 line with modifier JZ, which attests that the whole vial went into the patient

CMS has required one of the two modifiers on single-dose-vial drug claims since July 1, 2023. Claims carrying neither have been returned as unprocessable since October 1, 2023. Payment for waste is capped at the amount printed on the vial label, so the two lines together should never exceed 25 or 50 units.

Record the discarded amount in the patient’s chart as well as on the claim. That note is what supports the JW line if the drug charge is ever reviewed.

Codes that travel with J3101 on the same claim

J3101 rarely appears alone. The table below shows the codes most often billed alongside it, plus the adjacent codes coders check while working tenecteplase claims.

A drug claim also needs its administration line, and CPT 96374 is the code a single tenecteplase bolus takes. Bill it once per encounter alongside the drug itself.

There is no stroke-specific alternative. The J3101 descriptor, Injection, tenecteplase, 1 mg, is indication-neutral. The same code bills the stroke dose and the STEMI dose, and only the unit count and the diagnosis change.

What the record must show before you submit

Before a J3101 claim goes out, the note has to name four things. Those are the indication, the patient weight, the administered dose, and the clinical basis for thrombolysis.

Tenecteplase claims attract scrutiny because of the drug’s unit cost and the specificity thrombolytic therapy needs. So the habits that matter get set at the point of care, well before a claim reaches any scrubber.

• Indication: State whether the bolus treated acute ischemic stroke or acute STEMI. That single line decides which dose table and which ICD-10 series apply.
• Dose and route: Record the exact milligrams administered (not ordered), route (IV bolus), date, time, and administering clinician in the MAR
• Patient weight: Document the weight used to calculate the dose. This is auditable proof that the billed unit count is correct.
• Medical necessity: The note must carry presenting symptoms and the clinical basis for thrombolysis. For STEMI that means the ECG findings. For stroke it means the imaging that excluded hemorrhage, the deficit assessment, and the symptom onset time.
• Diagnosis specificity: Use the most specific code the record supports, from the I63 series for stroke or the I21 series for STEMI. Avoid I63.9 and I21.3 unless the site is genuinely not documented.
• NDC on the claim: Include the 11-digit NDC for the vial strength opened, on every Medicaid claim and on Medicare Advantage plans that require it
• Audit trigger awareness: Billing the maximum dose for every patient without weight documentation is a common audit trigger. On a stroke claim the maximum is 25 units, not 50.

Turn that into a short pre-submission pass. Five checks catch most of what comes back on a J3101 line.

1. Does the diagnosis series match the indication in the note, I63 for stroke or I21 for STEMI?
2. Do the units equal the milligrams in the MAR, and do they sit inside that indication’s maximum?
3. Is CPT 96374 on the claim for the bolus?
4. Is the NDC the one printed on the vial that was opened, in 11-digit format?
5. Does the drug line carry JW for waste, or JZ to attest there was none?

Those records are also what make a denial appealable later. Missing clinical evidence is the most common reason appeals fail. Having the note, the weight, and the NDC to hand before the deadline removes that risk.

Prior authorization rarely applies, but confirm the plan

Traditional Medicare (Parts A and B) does not require prior authorization for J3101 in most settings. Tenecteplase goes in during stroke and cardiac emergencies, where pre-approval is impractical.

Medicare Advantage plans operate differently. Some require prospective authorization for high-cost Part B drugs even in urgent settings, and many carve emergency events out of the standard workflow.

Commercial and Medicaid requirements vary and change regularly. Never assume a payer skips prior authorization based on a previous claim, and check the current policy before administration when the clinical situation permits. The AAPC HCPCS code lookup is a quick way to confirm the code’s current status and any billing notes attached to it.

• Traditional Medicare (FFS): PA generally not required for either labeled indication in an emergency
• Medicare Advantage: Confirm with the specific plan. Emergency exceptions may apply; document the emergency basis in the record.
• Commercial payers: PA policies vary. Check the payer portal or call the authorization line before administration when time permits.
• Medicaid / Medi-Cal: State-specific requirements; some states require PA for high-cost thrombolytics regardless of setting

How claims management software keeps J3101 lines clean

Manual J3101 billing goes wrong at four points. Those are the indication, the unit count tied to the weight tier, the NDC line, and the diagnosis linkage that triggers coverage.

Those four often live in four places. The MAR sits in the chart, the code sits in a lookup tab, and someone retypes both into the claim.

Practice management software like Pabau closes that distance by building the claim from the record itself. The service attached to the encounter lands on the charge line, and diagnosis slots are seeded from the client’s recorded problem list.

Full ICD-10-CM and HCPCS lookup libraries sit behind a search icon and refresh with each official release.

Before the send button unlocks, the system checks that the fields a claim cannot go without are filled, such as membership numbers and authorization codes.

The claim then goes out electronically. On US claims, remittance posting and claim-status tracking come back into the same record.

• Code lookup libraries: Search the current ICD-10-CM and HCPCS files from inside the claim, so J3101 gets checked against the official release
• Record-based pre-fill: The service on the encounter lands on the charge line, and diagnosis slots draw from the recorded problem list
• Required-field checks: A claim cannot be sent until the fields a payer requires are complete, which catches a blank authorization or membership number
• Remittance posting: On US claims, payments post back against the original line, so you can compare what J3101 paid with the rate you expected
• Claim-status tracking: Follow a submitted claim without a phone call to the payer

None of that picks the code for you. A coder still reads the indication and counts the milligrams, and no software should be trusted to do either.

What changes is how much of the claim gets retyped, and how many J3101 lines leave the practice missing something the payer needed. That is the job of claims software for practices.

Simplify HCPCS drug billing from charge capture to claim submission

Pabau’s claims management software builds the claim from the encounter record, checks that required fields are complete, and submits it electronically. Fewer J3101 lines come back for something the payer needed.

Book a demo

Conclusion

J3101 asks very little of a coder and punishes small mistakes hard. The unit field holds one number, and that number is wrong the moment someone reads the STEMI table against a stroke chart.

So build the indication into the charge rule, not just the weight. To see how it handles HCPCS drug lines from charge capture through remittance, book a demo.

Continue your research

Need to tell the two thrombolytic J-codes apart? HCPCS code J2997 covers alteplase billing, coverage, and reimbursement, which is the code J3101 is most often confused with.

Tempted to bill an unclassified drug code? HCPCS code J3490 explains when the unclassified code is correct, and why a drug with its own J-code never qualifies.

Billing the administration line as well as the drug? CPT code 96374 covers IV push billing, modifiers, and the documentation a single bolus needs.

Want to reduce rejections before submission? Clean claim submission covers the checklist every billing team should run before transmitting high-cost injectable claims.

Dealing with J3101 denials after adjudication? Denial management workflows outlines how to track, appeal, and prevent recurring denials on drug J-codes.

Frequently asked questions